Medicines, Rizzuto (Rna Foundation): “They will be increasingly personalized and also sustainable”

“Thanks to progress in the molecular understanding of diseases and research in the fields of gene therapy and RNA-based therapies, modern medicine finally has the tools to aim to offer personalized medicines to individual patients, without exposing the national healthcare system to costs unsustainable. It is one of the main objectives of the National Center that I preside over and which, thanks to Pnrr funding assigned by the MIUR, is responsible for coordinating the work of 46 partners, including public bodies, private entities and companies, from its headquarters in Padua”. He said it Rosario Rizzutopresident of the Rna Foundation – National Research Center – Development of gene therapy and drugs with RNA technology, speaking today in Padua on the occasion of the open day “Inclusive medicine: that is, everything you wanted to know about medicines and that you can now ask us”, which was held in the headquarters of the Department of Pharmaceutical Sciences of the University of Padua.

Department which for the first time hosts the public in its classrooms, in its teaching laboratories and in the Mock Pharmacy (the “fake pharmacy”). Objective of the initiative: to experiment, discover and talk about the inclusion of drugs in our lives and the different facets of drug science, what gravitates around this world, what there is to know about new therapies and the developments of research.

“The 46 partners, including public bodies, private entities and companies, are all excellent in their field of action – explains Rizzuto, host of the event – ​​they are organized into ten thematic clusters (“spokes”), of which five deal with vertical research on projects involving genetic diseases, tumors, neurodegenerative diseases, cardiovascular and metabolic diseases, infectious and inflammatory diseases. The remaining five follow transversal research projects on technologies enabling the production of drugs on an industrial scale. Alongside its primary mission, which consists in expanding RNA-based pharmacology and gene therapy, developing new drugs for precision medicine, the Center – concludes Rizzuto – also promotes the creation of cutting-edge physical infrastructures and the launching educational and high-tech entrepreneurial initiatives that contribute to improving the effectiveness and sustainability of the healthcare system”.